阿替普酶在高血压或糖尿病患者急性脑缺血中的使用趋势和结果:来自旁遮普南部的三级护理经验。

Muhammad Ahmad Mukhtar, Naila Tariq, Ayesha Mukhtar, Aimen Khalid, Amna Mukhtar, Rubina Mukhtar
{"title":"阿替普酶在高血压或糖尿病患者急性脑缺血中的使用趋势和结果:来自旁遮普南部的三级护理经验。","authors":"Muhammad Ahmad Mukhtar, Naila Tariq, Ayesha Mukhtar, Aimen Khalid, Amna Mukhtar, Rubina Mukhtar","doi":"10.2174/011871529X381588250612061045","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Stroke is the second leading cause of death and the third leading cause of disability worldwide, with hypertension and diabetes mellitus being its most prominent risk factors. This study aims to assess the utilization trends and clinical outcomes of Alteplase in patients presenting with acute cerebral ischemia and known history of hypertension and/or diabetes, within our local population in Southern Punjab, Pakistan-a region with limited stroke care infrastructure.</p><p><strong>Methods: </strong>This observational study was conducted at the emergency department of a tertiary care hospital. A total of 106 patients presenting with acute cerebral ischemia confirmed via CT scan and/or MRI were enrolled. All patients had a documented history of hypertension (n = 72), diabetes mellitus (n = 18), or both (n = 16). Patients who presented within 4.5 hours of symptom onset and met standard inclusion criteria were administered intravenous Alteplase as per AHA/ASA guidelines. Patients were divided into two groups: Group 1 (received Alteplase, n = 44) and Group 2 (did not receive Alteplase, n = 62). Outcomes were measured using the modified Rankin Scale (mRS) at 3 months post-intervention, with favorable recovery defined as mRS 0-2.</p><p><strong>Results: </strong>Of the 44 patients who received Alteplase, 66% (n = 29) achieved favorable outcomes (mRS 0-2). In contrast, only 39% (n = 24) of the 62 patients in the non-Alteplase group had favorable recovery. No significant increase in hemorrhagic complications was observed in the Alteplase group.</p><p><strong>Conclusion: </strong>In patients with acute cerebral ischemia and pre-existing hypertension or diabetes, the timely administration of Alteplase significantly improves functional outcomes. Despite its proven efficacy, access to thrombolytic therapy remains inadequate in public sector hospitals in Southern Punjab. Efforts must be made to expand stroke services and standardize acute stroke care across the region.</p>","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Utilization Trends and Outcomes of Alteplase in Acute Cerebral Ischemia among Patients with Hypertension or Diabetes: A Tertiary Care Experience from Southern Punjab.\",\"authors\":\"Muhammad Ahmad Mukhtar, Naila Tariq, Ayesha Mukhtar, Aimen Khalid, Amna Mukhtar, Rubina Mukhtar\",\"doi\":\"10.2174/011871529X381588250612061045\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Stroke is the second leading cause of death and the third leading cause of disability worldwide, with hypertension and diabetes mellitus being its most prominent risk factors. This study aims to assess the utilization trends and clinical outcomes of Alteplase in patients presenting with acute cerebral ischemia and known history of hypertension and/or diabetes, within our local population in Southern Punjab, Pakistan-a region with limited stroke care infrastructure.</p><p><strong>Methods: </strong>This observational study was conducted at the emergency department of a tertiary care hospital. A total of 106 patients presenting with acute cerebral ischemia confirmed via CT scan and/or MRI were enrolled. All patients had a documented history of hypertension (n = 72), diabetes mellitus (n = 18), or both (n = 16). Patients who presented within 4.5 hours of symptom onset and met standard inclusion criteria were administered intravenous Alteplase as per AHA/ASA guidelines. Patients were divided into two groups: Group 1 (received Alteplase, n = 44) and Group 2 (did not receive Alteplase, n = 62). Outcomes were measured using the modified Rankin Scale (mRS) at 3 months post-intervention, with favorable recovery defined as mRS 0-2.</p><p><strong>Results: </strong>Of the 44 patients who received Alteplase, 66% (n = 29) achieved favorable outcomes (mRS 0-2). In contrast, only 39% (n = 24) of the 62 patients in the non-Alteplase group had favorable recovery. No significant increase in hemorrhagic complications was observed in the Alteplase group.</p><p><strong>Conclusion: </strong>In patients with acute cerebral ischemia and pre-existing hypertension or diabetes, the timely administration of Alteplase significantly improves functional outcomes. Despite its proven efficacy, access to thrombolytic therapy remains inadequate in public sector hospitals in Southern Punjab. Efforts must be made to expand stroke services and standardize acute stroke care across the region.</p>\",\"PeriodicalId\":93925,\"journal\":{\"name\":\"Cardiovascular & hematological disorders drug targets\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-06-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiovascular & hematological disorders drug targets\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/011871529X381588250612061045\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular & hematological disorders drug targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/011871529X381588250612061045","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的:脑卒中是全球第二大死亡原因和第三大致残原因,高血压和糖尿病是其最主要的危险因素。本研究旨在评估阿替普酶在急性脑缺血和已知高血压和/或糖尿病病史患者中的应用趋势和临床结果,研究对象为巴基斯坦旁遮普省南部的当地人群,该地区卒中护理基础设施有限。方法:本观察性研究在一家三级医院的急诊科进行。共纳入106例经CT扫描和/或MRI确诊的急性脑缺血患者。所有患者均有高血压(n = 72)、糖尿病(n = 18)或两者兼有(n = 16)。在4.5小时内出现症状并符合标准纳入标准的患者按照AHA/ASA指南静脉注射阿替普酶。患者分为两组:1组(接受阿替普酶治疗,n = 44)和2组(未接受阿替普酶治疗,n = 62)。在干预后3个月,使用改良的Rankin量表(mRS)测量结果,以mRS 0-2定义为良好的恢复。结果:44例接受阿替普酶治疗的患者中,66% (n = 29)获得了良好的预后(mRS 0-2)。相比之下,非阿替普酶组62例患者中只有39% (n = 24)恢复良好。阿替普酶组出血并发症未见明显增加。结论:急性脑缺血合并既往高血压或糖尿病患者及时给予阿替普酶可显著改善功能预后。尽管证明了溶栓疗法的有效性,但在旁遮普南部的公立医院,获得溶栓疗法的机会仍然不足。必须努力扩大卒中服务,并在整个地区规范急性卒中护理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Utilization Trends and Outcomes of Alteplase in Acute Cerebral Ischemia among Patients with Hypertension or Diabetes: A Tertiary Care Experience from Southern Punjab.

Objective: Stroke is the second leading cause of death and the third leading cause of disability worldwide, with hypertension and diabetes mellitus being its most prominent risk factors. This study aims to assess the utilization trends and clinical outcomes of Alteplase in patients presenting with acute cerebral ischemia and known history of hypertension and/or diabetes, within our local population in Southern Punjab, Pakistan-a region with limited stroke care infrastructure.

Methods: This observational study was conducted at the emergency department of a tertiary care hospital. A total of 106 patients presenting with acute cerebral ischemia confirmed via CT scan and/or MRI were enrolled. All patients had a documented history of hypertension (n = 72), diabetes mellitus (n = 18), or both (n = 16). Patients who presented within 4.5 hours of symptom onset and met standard inclusion criteria were administered intravenous Alteplase as per AHA/ASA guidelines. Patients were divided into two groups: Group 1 (received Alteplase, n = 44) and Group 2 (did not receive Alteplase, n = 62). Outcomes were measured using the modified Rankin Scale (mRS) at 3 months post-intervention, with favorable recovery defined as mRS 0-2.

Results: Of the 44 patients who received Alteplase, 66% (n = 29) achieved favorable outcomes (mRS 0-2). In contrast, only 39% (n = 24) of the 62 patients in the non-Alteplase group had favorable recovery. No significant increase in hemorrhagic complications was observed in the Alteplase group.

Conclusion: In patients with acute cerebral ischemia and pre-existing hypertension or diabetes, the timely administration of Alteplase significantly improves functional outcomes. Despite its proven efficacy, access to thrombolytic therapy remains inadequate in public sector hospitals in Southern Punjab. Efforts must be made to expand stroke services and standardize acute stroke care across the region.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信